Market Cap
US$1.0b
Last Updated
2021/03/03 23:55 UTC
Data Sources
Company Financials +
Executive Summary
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Veru's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VERU is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 32% a week.
Volatility Over Time: VERU's weekly volatility has increased from 18% to 32% over the past year.
Market Performance
7 Day Return
-13.2%
VERU
-1.6%
US Personal Products
-3.4%
US Market
1 Year Return
219.2%
VERU
44.2%
US Personal Products
29.4%
US Market
Return vs Industry: VERU exceeded the US Personal Products industry which returned 44.2% over the past year.
Return vs Market: VERU exceeded the US Market which returned 29.4% over the past year.
Shareholder returns
| VERU | Industry | Market | |
|---|---|---|---|
| 7 Day | -13.2% | -1.6% | -3.4% |
| 30 Day | 36.4% | 14.9% | 0.6% |
| 90 Day | 300.9% | 17.5% | 6.3% |
| 1 Year | 219.2%219.2% | 45.1%44.2% | 32.2%29.4% |
| 3 Year | 692.2%692.2% | 62.8%56.4% | 51.3%41.7% |
| 5 Year | 432.4%432.4% | 109.4%93.1% | 119.6%95.2% |
Long-Term Price Volatility Vs. Market
How volatile is Veru's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Shareholders In Veru (NASDAQ:VERU) Should Look Beyond Earnings For The Full Story2 weeks ago | Simply Wall St
News Flash: Analysts Just Made An Incredible Upgrade To Their Veru Inc. (NASDAQ:VERU) Forecasts2 weeks ago | Simply Wall St
Here's Why Veru (NASDAQ:VERU) Can Manage Its Debt ResponsiblyValuation
Is Veru undervalued compared to its fair value and its price relative to the market?
574.09x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: VERU ($13.15) is trading above our estimate of fair value ($1.72)
Significantly Below Fair Value: VERU is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: VERU is poor value based on its PE Ratio (574.1x) compared to the US Personal Products industry average (19.5x).
PE vs Market: VERU is poor value based on its PE Ratio (574.1x) compared to the US market (21.4x).
Price to Earnings Growth Ratio
PEG Ratio: VERU is poor value based on its PEG Ratio (6.7x)
Price to Book Ratio
PB vs Industry: VERU is overvalued based on its PB Ratio (19.4x) compared to the US Personal Products industry average (2.6x).
Next Steps
Future Growth
How is Veru forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
85.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VERU's forecast earnings growth (85.3% per year) is above the savings rate (2%).
Earnings vs Market: VERU's earnings (85.3% per year) are forecast to grow faster than the US market (19.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: VERU's revenue (46.9% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: VERU's revenue (46.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VERU's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Veru performed over the past 5 years?
-30.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VERU has a large one-off gain of $4.3M impacting its December 31 2020 financial results.
Growing Profit Margin: VERU became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: VERU has become profitable over the past 5 years, growing earnings by -30% per year.
Accelerating Growth: VERU has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: VERU has become profitable in the last year, making it difficult to compare its past year earnings growth to the Personal Products industry (17.1%).
Return on Equity
High ROE: VERU's Return on Equity (3.2%) is considered low.
Next Steps
Financial Health
How is Veru's financial position?
Financial Position Analysis
Short Term Liabilities: VERU's short term assets ($47.6M) exceed its short term liabilities ($17.1M).
Long Term Liabilities: VERU's short term assets ($47.6M) exceed its long term liabilities ($7.0M).
Debt to Equity History and Analysis
Debt Level: VERU's debt to equity ratio (29.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if VERU's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: VERU's debt is not well covered by operating cash flow (8.6%).
Interest Coverage: VERU's interest payments on its debt are not well covered by EBIT (0.4x coverage).
Balance Sheet
Next Steps
Dividend
What is Veru current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VERU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VERU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VERU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VERU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: VERU is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VERU's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Mitch Steiner (59 yo)
4.42yrs
Tenure
US$1,263,303
Compensation
Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...
CEO Compensation Analysis
Compensation vs Market: Mitch's total compensation ($USD1.26M) is below average for companies of similar size in the US market ($USD2.20M).
Compensation vs Earnings: Mitch's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 4.42yrs | US$1.26m | 9.41% $ 97.0m | |
| Vice Chairman & Chief Corporate Officer | 3yrs | US$578.30k | 10.34% $ 106.6m | |
| CFO & Chief Administrative Officer | 3yrs | US$549.00k | 0.12% $ 1.3m | |
| Chief Scientific Officer | 2.5yrs | US$623.63k | 0% $ 0 | |
| Director of Investor Relations | 1.92yrs | no data | no data | |
| Executive VP of Legal & Secretary | 3.08yrs | no data | no data | |
| Executive Vice President of Corporate Development | 4.17yrs | no data | no data | |
| Executive Vice President for Medical Affairs | 1.17yrs | US$485.91k | no data | |
| Executive Vice President of Strategy & Commercial | no data | no data | no data | |
| Executive Vice President of Clinical Operations | 2.92yrs | no data | no data | |
| Senior Vice President of Quality Oversight | 2.08yrs | no data | no data |
3.0yrs
Average Tenure
59yo
Average Age
Experienced Management: VERU's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 4.42yrs | US$1.26m | 9.41% $ 97.0m | |
| Vice Chairman & Chief Corporate Officer | 3yrs | US$578.30k | 10.34% $ 106.6m | |
| Board Observer | 4.42yrs | no data | no data | |
| Independent Director | 3yrs | US$61.08k | 0.13% $ 1.3m | |
| Independent Director | 4.42yrs | US$61.08k | 0% $ 0 | |
| Independent Director | 4yrs | US$61.08k | 0.041% $ 427.3k | |
| Independent Director | 0.58yr | no data | 0.014% $ 148.5k |
3.0yrs
Average Tenure
61yo
Average Age
Experienced Board: VERU's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VERU insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.2%.
Top Shareholders
Company Information
Veru Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Veru Inc.
- Ticker: VERU
- Exchange: NasdaqCM
- Founded: 1971
- Industry: Personal Products
- Sector: Household
- Market Cap: US$1.030b
- Shares outstanding: 78.36m
- Website: https://www.verupharma.com
Number of Employees
Location
- Veru Inc.
- 48 NW 25th Street
- Suite 102
- Miami
- Florida
- 33127
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| VERU | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jul 1990 |
| FMW | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 1990 |
Biography
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection a...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/03 23:55 |
| End of Day Share Price | 2021/03/03 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.